Synta Pharma announces new ganetespib trials, shares rise

Synta Pharmaceuticals (SNTA) jumps 8% premarket.

The company announces the initiation of three new ganetespib trials.

The Leukemia & Lymphoma Research Fund and Cancer Research UK are supporting the studies, which will evaluate a ganetespib/ chemo combo as a first-line treatment for AML and high risk MDS. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs